News

Medicus Pharma Partners with Swanielle for Clinical Study Expansion

Medicus Pharma Partners with Swanielle for Clinical Study Expansion

Medicus Pharma Ltd. Expands Clinical Study in Asia Pacific

Medicus Pharma Ltd. (NASDAQ: MDCX) has exciting news to share regarding its collaboration with Swanielle Inc. This partnership aims to explore the expansion of the ongoing Phase 2 clinical study for the innovative treatment of Basal Cell Carcinoma (BCC) within the Asia-Pacific region.

Collaboration with Swanielle Inc.

The collaboration agreement allows Swanielle, a specialized healthcare consulting firm, to facilitate connections with pharmaceutical or biotech companies in Southeast Asia. This initiative will support Medicus in its ambition to broaden the Phase 2 clinical study, which is vital for gathering more comprehensive data on the treatment's safety and efficacy.

Current Phase 2 Clinical Study Progress

The Phase 2 clinical study, designated SKNJCT-003, is currently active across nine clinical sites in the United States. So far, the study has successfully randomized over 25% of the expected 60 participants. Looking ahead, Medicus plans to conduct an interim data analysis in the early months of 2025, followed by submitting findings to the FDA as part of preparations for a Type C meeting. This meeting aims to establish a clear path for the clinical development program, with the goal of transitioning from an exploratory trial to a pivotal trial.

Design and Objectives of the Clinical Trial

The SKNJCT-003 study is crafted as a randomized, double-blind, placebo-controlled trial intended to enroll up to 60 participants diagnosed with BCC of the skin. This clinical trial seeks to evaluate the treatment efficacy of two dose levels of D-MNA juxtaposed against a placebo control. Randomization will place subjects into one of three groups: a control group receiving a placebo, a low-dose group administering 100?g of D-MNA, and a high-dose group utilizing 200?g of D-MNA.

Safety and Tolerability Findings

Significantly, the 200?g dose of D-MNA was identified as the maximum dose employed in the previous Phase 1 safety and tolerability study (SKNJCT-001) concluded successfully in early 2021. The earlier trial met its key objective, demonstrating that D-MNA was well-tolerated by all participants without any dose-limiting toxicities or severe adverse events. Furthermore, assessments revealed no concerning systemic effects or significant abnormal laboratory findings.

Looking Forward

Dr. Raza Bokhari, Executive Chairman and CEO of Medicus, expressed enthusiasm about the advancements in their clinical development program. He emphasized the importance of collaborating with Swanielle to gather crucial data on the treatment's efficacy and safety. This partnership aims to enhance the evaluation of the pivotal trial that Medicus plans to embark upon shortly.

The agreement with Swanielle spans an initial duration of one year, starting from the beginning of December. Under this agreement, Swanielle will receive a retainer fee of $22,500, coupled with a variable success fee of 1% to 5%, contingent upon securing a definitive agreement with a reputable partner.

Contact Information

For inquiries regarding this partnership and ongoing trials, individuals can reach out to:

Carolyn Bonner, President
(610) 636-0184
cbonner@medicuspharma.com

Jeremy Feffer
LifeSci Advisors
(212) 915-2568
jfeffer@lifesciadvisors.com

About Medicus Pharma Ltd.

Medicus Pharma Ltd. is a dedicated biotech and life sciences company focused on introducing innovative and transformative therapeutic assets to the market. Through its wholly-owned subsidiary, SkinJect Inc., Medicus works on commercializing a groundbreaking non-invasive treatment for basal cell skin cancer. Utilizing a patented dissolvable microneedle patch allows for the targeted delivery of the chemotherapeutic agent designed to eradicate tumor cells effectively. The Phase 1 study conducted previously has encouraged the company to move forward with the IND clinical protocol for Phase 2 trials, continuing to uphold a commitment to advancing treatment methodologies in oncology.

Frequently Asked Questions

What is the goal of the collaboration between Medicus Pharma and Swanielle?

The collaboration aims to explore the expansion of the Phase 2 clinical study for Basal Cell Carcinoma treatment in the Asia-Pacific region.

What are the main findings from the Phase 1 study of D-MNA?

The Phase 1 study showed D-MNA was well-tolerated, with no severe adverse events or dose-limiting toxicities among participants.

What is the design of the SKNJCT-003 clinical trial?

The trial is a randomized, double-blind, placebo-controlled study evaluating the efficacy of two dosing levels of D-MNA compared to a placebo.

When can we expect updates on the interim data analysis?

An interim data analysis is scheduled for early 2025, with findings to be submitted to the FDA thereafter.

How can I contact Medicus Pharma for more information?

Interested parties can contact Carolyn Bonner at (610) 636-0184 or via email at cbonner@medicuspharma.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Berlin Heals Puts Microcurrent Therapy to a Real Test

Updated Category News Views 26

A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....

Continue Reading
Modexus Opens a $500 Million Buyback With Real Caveats

Updated Category News Views 68

A half-billion-dollar buyback authorization can make a stock crowd sit up fast, and Modexus Solutions has plainly chosen that moment. On November 18, 2026, the Racine, Wisconsin-based thermal-management company said its board authorized repurchases of up to $500 million of common stock. For holders of NYSE:MOD, that is a meaningful declaration of intent. It says...

Continue Reading
LRM Adds Two IND Studies Testing Injectable PDGF in Skin

Updated Category News Views 9

Under-eye medicine has a nasty habit of outrunning the evidence, which makes LRM's decision to put injectable rhPDGF-BB through more formal study worth watching. Lynch Regenerative Medicine has announced two FDA-accepted INDs for investigator-initiated clinical trials: one examining what the material does inside facial skin, the other testing it for infraorbital...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 187

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Perform.AI Tests Whether Stores Can Sell to Agents

Updated Category News Views 39

Shopping bots are about to become one more fussy customer standing in the aisle, except this one reads machine-facing files, rejects broken checkout steps, and does not care how pretty the homepage looks. Perform.AI has launched a free UCP and ACP Readiness Checker aimed at online retailers that need to know whether AI agents can find products, purchase them, and follow...

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 35

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 182

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 159

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
Texas Restaurants Get a New Read on Customer Demand

Updated Category News Views 148

Texas restaurant owners are being handed a sharper flashlight, and frankly it is overdue. HundredX and the Texas Restaurant Association have launched a pilot that gives TRA members access to the HundredX Restaurant Insights Platform, aiming to bring customer and market intelligence to the independent operators and regional chains that usually cannot pay big-company prices...

Continue Reading
Knowles Expands Its Teacher Pipeline With 39 Fellows

Updated Category News Views 32

Thirty-Nine Teachers Is Not a Trivial Signal Thirty-nine new math and science teachers may not rattle public markets, but it says plenty about where the real strain sits in American education. The Knowles Teacher Initiative has named its 2026 Teaching Fellowship class, its largest ever, and the timing is dead serious: schools are still wrestling with recruiting and...

Continue Reading

Top 5 Most Recently Viewed Articles

United Bank Secures Crucial $75M Tax Credit for Growth

Updated Category News Views 148

United Bank Receives Significant Tax Credit Allocation United Bank is excited to share that it has been awarded a substantial allocation of $75 million under the New Markets Tax Credit (NMTC) program. This funding, granted by the Department of the Treasury through its affiliated Community Development Entity, UB Community Development, is a testament to the bank's ongoing...

Continue Reading
Exploring Intangible Assets in ASEAN Capital Markets

Updated Category News Views 245

Understanding Intangible Assets in ASEAN Capital Markets Global consulting firm J.S. Held has collaborated with notable organizations to produce an insightful report examining the landscape of intangible assets in ASEAN capital markets. This partnership involves the International Valuation Standards Council (IVSC), the Intellectual Property Office of Singapore (IPOS), and...

Continue Reading
Festival Celebrates Community with Food and Support Services

Updated Category News Views 180

Union Station Homeless Services Teams with Boomtown Brewery Union Station Homeless Services (USHS) collaborates with Boomtown Brewery for a vibrant Summer Sampler Food Festival. This delightful event will showcase not just delicious food but also the spirit of community and cooperation. A Flavorful Afternoon to Remember Taking center stage will be the wide array of...

Continue Reading
Flowable Showcases Cutting-Edge AI Solutions at Gartner Event

Updated Category News Views 260

Flowable Presents Innovative AI Solutions at Gartner Symposium Flowable CEO and CTO to Showcase Responsible AI-Driven Solutions Flowable, a leader in intelligent automation and enterprise transformation, is set to exhibit and present at the renowned Gartner IT Symposium/Xpo 2025 in Barcelona, Spain. This significant gathering of IT professionals will take place from...

Continue Reading
Accounts Receivable Automation Market Set for Major Growth

Updated Category News Views 214

Transforming Financial Management: The Rise of Accounts Receivable Automation As businesses seek operational excellence, the Accounts Receivable (AR) automation market is on a remarkable upswing. It's set to hit USD 3.8 billion by 2033, sporting a compound annual growth rate (CAGR) of 12.5% from 2024 to 2033. This trend signifies a notable change in how companies handle...

Continue Reading